[Hereditary angiœdema treatments: Recommendations from the French national center for angiœdema (Bordeaux consensus 2014)].
Treatment of hereditary angiœdema (HAE), associated or not with C1Inh deficiency, has dramatically changed these last five years. Four new therapeutic options are now available in France. The French Reference Centre for Angioedema has a consensus meeting to give recommendations about their use. The proposals were based on a CREAK survey and a comprehensive review of the literature done by 4 experts. These proposals were submitted to a vote at a national CREAK meeting (Bordeaux, March 2014). Fifty-one participants, 15 experts and one expert-patient have participated. The consensus concerned HAE patients with or without C1Inh deficiency. Were excluded children, patients with acquired AE and with drug induced AE. Proposals were done for 4 cases: acute attack treatment, short-term prophylaxis, long-term prophylaxis and pregnant women. The drugs cited were: C1Inh concentrate, icatibant, tranexamic acid, danazol and chlormadinone acetate. Consensual proposals were obtained during this meeting. They will be now widely diffused.